Login
E-mail
Password
Mostra password
Ricorda
Password dimenticata?
Iscriviti gratuitamente
Registrazione
Registrazione
Parametri
Parametri
Quotazioni dinamiche 
OFFON

MIRATI THERAPEUTICS, INC.

(MRTX)
RiassuntoQuotazioniGraficiNotizieRatingAgendaSocietąFinanzaConsensusRevisioniDerivati 
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su MIRATI THERAPEUTICS, INC.
23/11Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
22/11Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination ..
17/11Mirati Therapeutics Submits Investigational New-Drug Application to FDA for MRTX1719 to..
17/11Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S..
17/11Mirati Therapeutics, Inc. Announces Submission of Investigational New Drug Application ..
12/11Mirati Therapeutics Announces Proposed Public Offering of Common Stock 11/09/2021 - For..
12/11MIRATI THERAPEUTICS, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
11/11Mirati Therapeutics Announces Pricing of Public Offering of Common Stock
09/11MIRATI THERAPEUTICS, INC.: Other Events, Financial Statements and Exhibits (form 8-K)
09/11Mirati Therapeutics Announces Proposed Public Offering of Common Stock
09/11Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
08/11Mirati Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
08/11Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate U..
08/11MIRATI: Q3 Earnings Snapshot
08/11Mirati Therapeutics Q3 Loss Narrows as Revenue Surges
08/11MIRATI THERAPEUTICS, INC.: Results of Operations and Financial Condition, Other Events, F..
08/11Earnings Flash (MRTX) MIRATI THERAPEUTICS Posts Q3 Revenue $71.8M
08/11Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate U..
04/11SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirat..
01/11Novavax, Harley-Davidson rise; Moderna, Mirati fall
01/11Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corpo..
01/11Health Care Stocks Recover Late, End Just Below Flatline
01/11Health Care Stocks Slightly Lower to Begin New Week
01/11Mirati Therapeutics COO, Chief Medical Officer Depart; Launches CFO Search -- Shares Dr..
01/11STATEMENT: Updates to Mirati Therapeutics Executive Leadership Team
01/11MIRATI THERAPEUTICS, INC.: Change in Directors or Principal Officers, Regulation FD Discl..
01/11Mirati Therapeutics, Inc. Announces Executive Changes
07/10MIRATI THERAPEUTICS: to Partner With Sanofi on Adagrasib-SAR442720 Combo Lung Cancer Tria..
07/10MIRATI THERAPEUTICS: to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination..
04/10MIRATI THERAPEUTICS: to Present New Research From its Innovative Oncology Pipeline at the..
24/09MIRATI THERAPEUTICS: Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
20/09MIRATI THERAPEUTICS: Reports Results From Phase 2 Study of MRTX-500
20/09MIRATI THERAPEUTICS: Names David Meek as CEO
20/09MIRATI THERAPEUTICS: Charles M. Baum, M.D., Ph.D to Continue in New Role of President, Fo..
20/09MIRATI THERAPEUTICS: Announces Long-term Survival Results from an Exploratory Analysis of..
20/09Mirati Therapeutics, Inc. announces results from a post hoc exploratory analysis of the..
20/09MIRATI THERAPEUTICS, INC.: Change in Directors or Principal Officers, Other Events, Finan..
20/09Mirati Therapeutics, Inc. Announces Changes in Chief Executive Officer
20/09MIRATI THERAPEUTICS: Reports Positive Phase 2 Trial Results for Potential Cancer Drug Ada..
20/09MIRATI THERAPEUTICS: Appoints David Meek as Chief Executive Officer
20/09MIRATI THERAPEUTICS: taps industry veteran Meek as CEO
20/09Mirati Therapeutics Appoints David Meek to BOD
20/09MIRATI THERAPEUTICS: Announces Positive Phase 2 Topline Results for Investigational Adagr..
20/09Mirati Therapeutics, Inc. Announces Positive Phase 2 Topline Results for Investigationa..
19/09MIRATI THERAPEUTICS: Presents Positive Clinical Data with Investigational Adagrasib as Mo..
19/09Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as M..
19/09MIRATI THERAPEUTICS: drug combination shrinks tumors in 39% of colon cancer patients in s..
15/09MIRATI THERAPEUTICS: to Host Virtual Investor Event on Monday, September 20, 2021
25/08MIRATI THERAPEUTICS: Clinical Research at ESMO Congress 2021 to Highlight Progress with I..
05/08MIRATI: Q2 Earnings Snapshot
05/08Mirati Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30..
05/08MIRATI THERAPEUTICS: Reports Second Quarter 2021 Financial Results and Recent Corporate U..
02/07MIRATI THERAPEUTICS, INC.: Other Events (form 8-K)
28/06MIRATI THERAPEUTICS, INC.: Change in Directors or Principal Officers (form 8-K)
28/06Mirati Therapeutics, Inc. Announces Board Changes
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell 1000 Value Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell 3000E Value Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) dropped from Russell 2000 Dynamic Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell 1000 Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) dropped from Russell 2000 Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell 1000 Dynamic Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell Midcap Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell Midcap Growth Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell Midcap Value Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell 3000 Value Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell 2500 Value Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell Small Cap Comp Value Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) added to Russell 1000 Growth Index
25/06MIRATI THERAPEUTICS, INC.(NASDAQGS: MRTX) dropped from Russell 2000 Growth Index
24/06MIRATI THERAPEUTICS: Cancer Drug Candidate Wins Breakthrough Therapy Designation from FDA..
24/06MIRATI THERAPEUTICS': Adagrasib Receives Breakthrough Therapy Designation from U.S. Food ..
24/06Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food..
02/06MIRATI THERAPEUTICS: to Take Part in the 42nd Annual Goldman Sachs Global Healthcare Conf..
02/06Zai Lab Partners with Mirati Therapeutics to Develop, Commercialize Experimental Cancer..
01/06MIRATI THERAPEUTICS, INC.: Entry into a Material Definitive Agreement, Financial Statemen..
1  2  3  4Pross.
Prossimo evento su MIRATI THERAPEUTICS, INC.
10/03/22